UPDATE: Incyte (INCY) Tops Q3 EPS by 12c, Beats on Revenues; Boosts FY17 Jakafi Net Product Revenue Guidance

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/20/2026

1. SPY
2. XENE
3. NUE
4. HUBS
5. RTB
6. ONON
7. AAPL
8. TRMD
9. ACN
10. AZN

Go back to UPDATE: Incyte (INCY) Tops Q3 EPS by 12c, Beats on Revenues; Boosts FY17 Jakafi Net Product Revenue Guidance

Incyte (INCY), AstraZeneca (AZN) Expand Clinical Trial Collaboration in Early Lung Cancer

October 31, 2017 6:20 AM EDT

Incyte Corporation (Nasdaq: INCY) and MedImmune, AstraZenecas (NYSE: AZN) global biologics research and development arm, today announced the expansion of their clinical collaboration. As part of the agreement, the companies will evaluate the efficacy and safety of epacadostat, Incytes investigational selective IDO1 enzyme inhibitor, in combination with AstraZenecas Imfinzi® (durvalumab), a human monoclonal antibody directed against PD-L1, compared to Imfinzi alone.

The exclusive collaboration for the study population allows the two companies to conduct a Phase 3 trial in patients with locally-advanced (Stage III), unresectable non-small cell lung... More

Incyte Corporation (INCY) Appoints Jacqualyn A. Fouse, Ph.D to Board

October 30, 2017 4:47 PM EDT

Incyte Corporation (NASDAQ: INCY) today announced the appointment of Jacqualyn Jackie A. Fouse, Ph.D., as a new member of the Board of Directors, effective November 14, 2017.

We are pleased to welcome Jackie to Incyte. Her impressive background will further strengthen and add to the experience of our Board and leadership team, stated Hervé Hoppenot, Incytes Chairman and Chief Executive Officer. We look forward to... More